BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 26871476)

  • 21. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
    Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G
    Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes.
    Belickova M; Vesela J; Jonasova A; Pejsova B; Votavova H; Merkerova MD; Zemanova Z; Brezinova J; Mikulenkova D; Lauermannova M; Valka J; Michalova K; Neuwirtova R; Cermak J
    Oncotarget; 2016 Jun; 7(24):36266-36279. PubMed ID: 27167113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
    Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
    Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
    Papageorgiou SG; Vasilatou D; Kontos CK; Kotsianidis I; Symeonidis A; Galanopoulos AG; Hatzimichael E; Megalakaki A; Poulakidas E; Diamantopoulos P; Vassilakopoulos TP; Zikos P; Papadaki H; Mparmparousi D; Bouronikou E; Panayiotidis P; Viniou NA; Pappa V
    Am J Hematol; 2018 Jul; 93(7):895-901. PubMed ID: 29659040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study.
    Hatoum HT; Lin SJ; Buchner D; Kim E
    Curr Med Res Opin; 2011 Jun; 27(6):1255-62. PubMed ID: 21554144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
    Subari S; Baidoun F; Hreh M; Patnaik M; Hashmi S; Elliott M; Hogan W; Litzow M; Al-Kali A
    Int J Hematol; 2016 Apr; 103(4):409-15. PubMed ID: 26781617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.
    Wang W; Routbort MJ; Tang Z; Ok CY; Patel KP; Daver N; Garcia-Manero G; Medeiros LJ; Wang SA
    Eur J Haematol; 2017 Dec; 99(6):536-543. PubMed ID: 28926144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes.
    Haider M; Duncavage EJ; Afaneh KF; Bejar R; List AF
    Am Soc Clin Oncol Educ Book; 2017; 37():480-494. PubMed ID: 28561687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Characteristics, Prognosis, and Treatment Strategies of TP53 Mutations in Myelodysplastic Syndromes.
    Fang K; Qi J; Zhou M; Zhang Z; Han Y
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):224-235. PubMed ID: 34690091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
    Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
    Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
    Cabezón M; Malinverni R; Bargay J; Xicoy B; Marcé S; Garrido A; Tormo M; Arenillas L; Coll R; Borras J; Jiménez MJ; Hoyos M; Valcárcel D; Escoda L; Vall-Llovera F; Garcia A; Font LL; Rámila E; Buschbeck M; Zamora L;
    Clin Epigenetics; 2021 Jan; 13(1):9. PubMed ID: 33446256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome.
    Sohn SK; Moon JH; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Park SW; Lee WS; Lee SM; Kim H; Lee HS; Kim YS; Cho YY; Bae SH; Lee JH; Kim SH; Song IC; Kwon JH; Lee YJ
    Korean J Intern Med; 2018 Nov; 33(6):1194-1202. PubMed ID: 29232940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.
    Chang CK; Zhao YS; Xu F; Guo J; Zhang Z; He Q; Wu D; Wu LY; Su JY; Song LX; Xiao C; Li X
    Br J Haematol; 2017 Feb; 176(4):600-608. PubMed ID: 27984642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical implications and prognostic value of TP53 gene mutation and deletion in patients with myelodysplastic syndromes].
    Huang HJ; Shi ZX; Li B; Qin TJ; Xu ZF; Zhang HL; Fang LW; Hu NB; Pan LJ; Qu SQ; Liu D; Cai YN; Zhang YD; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):215-221. PubMed ID: 30929389
    [No Abstract]   [Full Text] [Related]  

  • 35. Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.
    Tobiasson M; McLornan DP; Karimi M; Dimitriou M; Jansson M; Ben Azenkoud A; Jädersten M; Lindberg G; Abdulkadir H; Kulasekararaj A; Ungerstedt J; Lennartsson A; Ekwall K; Mufti GJ; Hellström-Lindberg E
    Oncotarget; 2016 Apr; 7(16):22103-15. PubMed ID: 26959885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
    J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.
    Cluzeau T; Mounier N; Karsenti JM; Richez V; Legros L; Gastaud L; Garnier G; Re D; Montagne N; Gutnecht J; Gabriel Fuzibet J; Auberger P; Raynaud S; Cassuto JP
    Am J Hematol; 2013 Sep; 88(9):780-3. PubMed ID: 23757315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting TP53 Mutations in Myelodysplastic Syndromes.
    Hunter AM; Sallman DA
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):421-440. PubMed ID: 32089220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome.
    Park S; Baek DW; Sohn SK; Ahn JS; Kim HJ; Shin HJ; Chung JS; Lee SM; Lee WS; Lim SN; Lee YJ; Choi Y; Lee HS; Cho YY; Lee GW; Moon JH
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e367-e373. PubMed ID: 31060990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
    Bories P; Prade N; Lagarde S; Cabarrou B; Largeaud L; Plenecassagnes J; Luquet I; De Mas V; Filleron T; Cassou M; Sarry A; Fornecker LM; Simand C; Bertoli S; Recher C; Delabesse E
    PLoS One; 2020; 15(10):e0238795. PubMed ID: 33001991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.